Efficacy and safety evaluation of high-dose Vitamin B6 injection combined with 20AA Compound Amino Acid injection in treatment of Amyotrophic Lateral Sclerosis (ALS)

Evaluation of the efficacy and safety of high-dose vitamin B6 injection combined with 20AA compound amino acid injection in the treatment of amyotrophic lateral sclerosis: a multicenter retrospective study based on real world data

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300075878

Enrollment

Unknown

Registered

2023-09-18

Start date

2023-10-01

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Interventions

Treatement Group(single arm study): ALS patients treated with new therapies for at least 28 days

:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. ALS patients who meet GCC diagnostic criteria; 2. Aged >= 18 years old; 3. The treatment process and therapeutic drugs are clearly recorded.

Exclusion criteria

Exclusion criteria: 1. Medical records record patients with spinal cord and brain stem tumors, malignant tumors, severe infections, and severe trauma; 2. The patient had serious liver and kidney diseases as recorded in his medical records.

Design outcomes

Primary

Measure	Time frame
Overall Survival;	—

Secondary

Measure	Time frame
Survival Time;1-5 year Survival Rate after onset;	—

Countries

China

Contacts

Public ContactYin Jinnan

Changzhou Wujin People's Hospital

qinhongzmc@163.com+86 139 6129 6010

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026